Curevac | Pandemic PACT Tracker

Key facts

Disease
COVID-19
Known Financial Commitments (USD)
$15,300,000
Funder
Coalition for Epidemic Preparedness Innovations (CEPI)
Principal Investigator
N/A
Research Location
Germany
Lead Research Institution
Curevac
Research Priority Alignment
N/A

Research Category
Vaccines research, development and implementation
Research Subcategory
Phase 1 clinical trial
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Clinical Trial, Phase I
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified

Abstract

mRNA Full Length S stabilized (unmodified and codon optimized) Phase I safety and immunogenicity

Publicationslinked via Europe PMC

Last Updated:9 hours ago

View all publications at Europe PMC

Midlife women's stress and burnout: associations with health-related quality of life, physical activity, and physical function.

Personalizing smoking cessation pharmacotherapy using neuroaffective reactivity profiles: A randomized controlled trial.

Investigators are human too: outcome bias and perceptions of individual culpability in patient safety incident investigations.

Comparison of Patients Seen by an Embedded Social Worker and Nurse Practitioner Palliative Care Model in Hospital Medicine Versus Referral-Based Specialty Palliative Care and Their Acute Care Utilization Outcomes.

Trimester of diagnosis affects tumor characteristics and survival in breast cancer during pregnancy: first results from the STURGATE collaboration.

"Whatever you asked for you got": the impact of charitable funding of paediatric oncology in the UK - from 1960 to 2000.

Potent and dose-sparing next-generation SARS-CoV-2 vaccine, mRNA-1283, induces polyfunctional and durable T cell immunity.

Coping strategies among acute and critical care nurses: a scoping review.

AAV8 gene therapy and dietary insults together precipitate cholestatic liver disease in a mouse model of X-linked myotubular myopathy.